S. 3031

To authorize Drug Free Communities enhancement grants to address major emerging drug issues or local drug crises.

IN THE SENATE OF THE UNITED STATES

February 24, 2010

Mr. Leahy (for himself and Mr. Grassley) introduced the following bill; which was read twice and referred to the Committee on the Judiciary

A BILL

To authorize Drug Free Communities enhancement grants to address major emerging drug issues or local drug crises.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Drug Free Commu-
- 5 nities Enhancement Act of 2010".
- 6 SEC. 2. FINDINGS.
- 7 Congress finds the following:
- 8 (1) The epidemiology of drug use indicates that
- 9 emerging drug trends increase over a short period of
- time and tend to cluster in discrete geographic

- areas. Historical evidence shows that emerging local drug issues and crises can be stopped or mitigated before they spread to other areas, if they are identified quickly and addressed in a comprehensive multisector manner.
 - (2) Federal investments in drug prevention should not be solely based on national data and trends, but must be flexible enough to address emerging local problems and local drug crises before they become national trends.
 - (3) Successful drug prevention must be based on local data and involve multiple community sectors in planning and implementing specifically targeted strategies that respond to the unique drug problems of the community.
 - (4) Data and outcomes show that effective community coalitions can markedly reduce local drug use rates for drugs such as marijuana and inhalants among school-aged youth.
 - (5) Community coalitions are singularly situated to deal with emerging drug issues and local drug crises, such as methamphetamine, cheese (a mixture of black tar heroin and Tylenol PM), and prescription and non-prescription drug abuse because the community coalitions are organized, data

1	driven, and take a comprehensive, multi-sector ap-
2	proach to solving and addressing locally identified
3	drug problems.
4	(6) Providing enhancement grants to coalitions
5	to address emerging local drug issues or local drug
6	crises is a cost effective way to deal with these drug
7	issues. This approach builds on existing infrastruc-
8	tures with proven results that include all of the rel-
9	evant community sectors needed to comprehensively
10	address specific emerging drug issues and crises
11	and guards against using Federal funding to create
12	duplicative community based infrastructures for sub-
1 4	-
13	stance abuse prevention.
	stance abuse prevention. SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT
13	
13 14	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT
13 14 15	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG
13 14 15 16	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG ISSUES OR LOCAL DRUG CRISES.
13 14 15 16	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG ISSUES OR LOCAL DRUG CRISES. (a) DEFINITIONS.—In this section—
113 114 115 116 117 118	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG ISSUES OR LOCAL DRUG CRISES. (a) DEFINITIONS.—In this section— (1) the term "Director" means the Director of
113 114 115 116 117 118 119	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG ISSUES OR LOCAL DRUG CRISES. (a) DEFINITIONS.—In this section— (1) the term "Director" means the Director of the Office of National Drug Control Policy;
13 14 15 16 17 18 19 20	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG ISSUES OR LOCAL DRUG CRISES. (a) DEFINITIONS.—In this section— (1) the term "Director" means the Director of the Office of National Drug Control Policy; (2) the term "drug" means—
13 14 15 16 17 18 19 20 21	SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT GRANTS TO ADDRESS EMERGING DRUG ISSUES OR LOCAL DRUG CRISES. (a) DEFINITIONS.—In this section— (1) the term "Director" means the Director of the Office of National Drug Control Policy; (2) the term "drug" means— (A) a substance listed on schedule I, II

1	(C) if used in a manner that is illegal, a
2	prescription or over the counter drug or medi-
3	cine; and
4	(D) another mind altering substance with
5	the potential for abuse, as determined by the
6	Director, not listed on a schedule of section
7	202(e) of the Controlled Substance Act (21
8	U.S.C. 812(c));
9	(3) the term "emerging local drug issue"
10	means, with respect to the area served by an eligible
11	entity, a sudden increase in the use or abuse of a
12	particular drug in the community, as documented by
13	local data;
14	(4) the term "local drug crisis" means, with re-
15	spect to the area served by an eligible entity, the use
16	of a specific drug in the area at levels that are sig-
17	nificantly higher than the national average, over a
18	sustained period of time, as documented by local
19	data; and
20	(5) the term "eligible entity" means an organi-
21	zation that—
22	(A) is receiving or has received a grant
23	under chapter 2 of title I of the National Nar-
24	cotics Leadership Act of 1988 (21 U.S.C. 1521

1	et seq.) (commonly known as the Drug-Free
2	Communities Act of 1997); and
3	(B) has documented, using local data—
4	(i) for an emerging local drug issue—
5	(I) rates of drug use and abuse
6	above the national average, as deter-
7	mined by the Director (including ap-
8	propriate consideration of the Moni-
9	toring of the Future Survey published
10	by the Department of Health and
11	Human Services), for comparable time
12	periods; or
13	(II) if national data is not avail-
14	able, at the discretion of the Director,
15	high rates of drug use or abuse based
16	solely on valid local data; or
17	(ii) for a local drug crisis—
18	(I) rates of use and abuse for a
19	specific drug at levels that are signifi-
20	cantly higher than the national aver-
21	age, as determined by the Director
22	(including appropriate consideration
23	of the Monitoring of the Future Sur-
24	vey published by the Department of
25	Health and Human Services and the

National Survey on Drug Use and
Health by the Substance Abuse and
Mental Health Service Administration); and

(II) rates of use and abuse for a

- (II) rates of use and abuse for a specific drug that continue over a sustained period of time, as determined by the Director.
- 9 (b) AUTHORIZATION OF PROGRAM.—The Director 10 may make enhancement grants to eligible entities to im11 plement comprehensive community-wide strategies that 12 address emerging local drug issues or local drug crises 13 within the area served by the eligible entity.

(c) APPLICATION.—

- (1) IN GENERAL.—An eligible entity desiring an enhancement grant under this section shall submit an application to the Director at such time, in such manner, and accompanied by such information as the Director may require.
- (2) Criteria.—As part of an application for a grant under this section, the Director shall require an eligible entity to submit a detailed, comprehensive, multi-sector plan for addressing the emerging local drug issue or local drug crises within the area served by the eligible entity.

1	(d) Uses of Funds.—A grant under this section
2	shall be used to—
3	(1) implement comprehensive, community-wide
4	prevention strategies to address an emerging local
5	drug issue or drug crises in the area served by an
6	eligible entity, in accordance with the plan submitted
7	under subsection (e)(2); and
8	(2) obtain specialized training and technical as-
9	sistance from the entity receiving a grant under sec-
10	tion 4 of Public Law 107–82 (21 U.S.C. 1521 note).
11	(e) Grant Amounts.—
12	(1) In general.—The total amount of grant
13	funds awarded to an eligible entity for a fiscal year
14	may not exceed the amount of non-Federal funds
15	raised by the eligible entity, including in-kind con-
16	tributions, for that fiscal year.
17	(2) Grant awards.—A grant under this sec-
18	tion shall—
19	(A) be made for a period of not more than
20	4 years; and
21	(B) be for not more than \$75,000 per
22	year.
23	(f) Supplement Not Supplant.—Grant funds pro-
24	vided under this section shall be used to supplement, not

- 1 supplant, Federal and non-Federal funds available for car-
- 2 rying out the activities described in this section.
- 3 (g) EVALUATION.—A grant under this section shall
- 4 be subject to the same evaluation requirements and proce-
- 5 dures as the evaluation requirements and procedures im-
- 6 posed on the recipient of a grant under chapter 2 of title
- 7 I of the National Narcotics Leadership Act of 1988 (21
- 8 U.S.C. 1521 et seq.) (commonly known as the Drug-Free
- 9 Communities Act of 1997).
- 10 (h) Administrative Expenses.—Not more than 5
- 11 percent of the amount appropriated to carry out this sec-
- 12 tion for any fiscal year may be used by the Director for
- 13 administrative expenses.
- 14 (i) AUTHORIZATION OF APPROPRIATIONS.—There
- 15 are authorized to be appropriated \$5,000,000 for each of
- 16 fiscal years 2011 through 2015 to carry out this section.

 \bigcirc